Toshiyuki Sakurai

Toshiyuki Sakurai

Auto-generated profile, based on publicly available information

Toshiyuki Sakurai

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SAShintaro Akiyama
Shintaro Akiyama
HSHiromichi Shimizu
Hiromichi Shimizu
ATAkiko Tamura
Akiko Tamura
KYKaoru Yokoyama
Kaoru Yokoyama
TSToshiyuki Sakurai
Toshiyuki Sakurai
TFToshimitsu Fujii
Toshimitsu Fujii

17 March 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SAShintaro Akiyama
Shintaro Akiyama
KYKaoru Yokoyama
Kaoru Yokoyama
SYSoichi Yagi
Soichi Yagi
Shinichiro ShinzakiShinichiro Shinzaki
Shinichiro Shinzaki
KTKozo Tsuruta
Kozo Tsuruta
TFToshimitsu Fujii
Toshimitsu Fujii

14 February 2022 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
TSToshiyuki Sakurai
Toshiyuki Sakurai
YAYoshihiro Akita
Yoshihiro Akita
HMHaruna Miyashita
Haruna Miyashita
RMRyosuke Miyazaki
Ryosuke Miyazaki
YMYuki Maruyama
Yuki Maruyama
MSMasayuki Saruta
Masayuki Saruta
Background and Aim: Ulcerative colitis (UC) is usually detected by clinical symptoms, such as bleeding and diarrhea; however, it is rather difficult to assess during asymptomatic clinical remission (CR). Hence, there is a need for a biomarker that can reliably detect UC during remission. We previously reported on the utility of the prostaglandin E‐major urinary metabolite (PGE‐MUM) as a biomarker reflecting UC activity. In this study, we evaluated the effectiveness of the PGE‐MUM in the diagnosis of endoscopic, histological, and histo‐endoscopic mucosal remission of UC, comparing with fecal tests.Methods: This prospective study was conducted at the Jikei University Hospital between August 2017 and January 2021. Patients with UC in CR scheduled to undergo colonoscopy were included. The association between the PGE‐MUM with endoscopic remission (ER), histological remission (HR), and complete mucosal healing (CMH, defined as histo‐endoscopic remission) was analyzed. We also compared the area under the curve (AUC) for the receiver operating characteristic curves between PGE‐MUM, fecal calprotectin (FC), and fecal immunochemical test (FIT).Results: In total, 128 patients were analyzed. PGE‐MUM differed significantly in ER versus non‐ER (14.5 vs 16.7, P = 0.028), HR versus non‐HR (14.2 vs 17.4, P = 0.004), and CMH versus non‐CMH (14.3 vs 16.7, P = 0.021). There were no significant differences between the AUCs for PGE‐MUM, FC, and FIT for ER, HR, or CMH.Conclusions: The PGE‐MUM can determine CMH in UC even during CR, regardless of the disease phenotype, indicating its clinical benefit for non‐invasive monitoring.

1 January 2007 in Internal Medicine
Verified
Journal Article
Open access
PDF file
SMSatoshi Morimoto
Satoshi Morimoto
TITakehiko Izumi
Takehiko Izumi
TSToshiyuki Sakurai
Toshiyuki Sakurai
KKKimiaki Komukai
Kimiaki Komukai
MKMakoto Kawai
Makoto Kawai
SMSeibu Mochizuki
Seibu Mochizuki
Acute aortic dissection of Stanford type A with intramural hematoma was diagnosed based on computed tomography (CT) findings in a 60-year-old man. During medical treatment, pulmonary embolism and deep vein thrombosis developed. CT revealed thrombosis in the right pulmonary artery, and 99mTc pulmonary perfusion scintigraphy showed defects in the right lung field. CT showed thrombus in the common iliac vein. An inferior vena caval filter was placed because anticoagulation therapy was contraindicated. A CT scan before discharge showed no thrombus in the pulmonary artery or common iliac vein, but a newly captured thrombus was found inside the filter.

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
MSMasayuki Saruta
Masayuki Saruta
TSToshiyuki Sakurai
Toshiyuki Sakurai
SGSPREAD-J group
SPREAD-J group

28 September 2026 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
FHFumihito Hirai
Fumihito Hirai
Katsuyoshi MatsuokaKatsuyoshi Matsuoka
Katsuyoshi Matsuoka
KWKenji Watanabe
Kenji Watanabe
RHRyota Hokari
Ryota Hokari
TKTaku Kobayashi
Taku Kobayashi
THTadakazu Hisamatsu
Tadakazu Hisamatsu
Background: Carotegrast methyl is an oral α4-integrin antagonist used to induce remission in patients with ulcerative colitis with an inadequate response to 5-aminosalicylate (5-ASA). This multicenter, retrospective observational study evaluated the clinical usefulness of carotegrast methyl in real-world practice. Methods: Patients with an inadequate response to 5-ASA who received carotegrast methyl were included. Clinical data were collected during and after treatment for up to 52 weeks. The primary endpoint was the response rate at week 8. The remission rate at week 8, response/remission rate at end of treatment, cumulative response/remission rate, and adverse drug reactions were also assessed. Effectiveness was evaluated using the patient reported outcomes-2 measure (sum of Mayo subscores for stool frequency and rectal bleeding). Results: Data were collected from 196 patients, of whom 180 were evaluable for effectiveness. The PRO-2-defined response and remission rates at week 8 were 57.8% and 43.3%, respectively, and the rates at the end of treatment (median treatment duration: 83.5 days) were 58.9% and 50.0%, respectively. The cumulative PRO-2-defined response/remission rates increased until week 16, followed by a slight further increase. Adverse drug reactions occurred in 31 of 196 patients (15.8%, 43 events), with no serious events. Conclusions: In terms of patient-reported symptom improvement, carotegrast methyl is an effective and well-tolerated treatment for patients with ulcerative colitis who have an inadequate response to 5-ASA. A substantial proportion of patients responded to 8 weeks of treatment. Continued treatment for up to 16 weeks may improve symptoms, even in patients with insufficient response at week 8.